Andrew R Reynolds
Overview
Explore the profile of Andrew R Reynolds including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
3411
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reynolds A, Moschetta M, Yohannes A, Walcott F, Ashford M, Szucs Z, et al.
Cancer Discov
. 2023 Apr;
13(5):1058-1083.
PMID: 37067191
Significance: The huge potential public health benefits of preventing cancer, combined with recent advances in the availability of novel early detection technologies and new treatment modalities, has caused us to...
2.
Cuypers A, Teuwen L, Bridgeman V, de Rooij L, Eelen G, Dewerchin M, et al.
STAR Protoc
. 2022 Sep;
3(4):101691.
PMID: 36173713
Tumor vessel co-option, a process in which cancer cells "hijack" pre-existing blood vessels to grow and invade healthy tissue, is poorly understood but is a proposed resistance mechanism against anti-angiogenic...
3.
Latacz E, Hoppener D, Bohlok A, Leduc S, Tabaries S, Moro C, et al.
Br J Cancer
. 2022 Jun;
127(6):988-1013.
PMID: 35650276
The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of liver metastases were established in 2017. Since then, numerous studies have applied these guidelines, have further substantiated the...
4.
Rada M, Kapelanski-Lamoureux A, Petrillo S, Tabaries S, Siegel P, Reynolds A, et al.
Commun Biol
. 2021 Aug;
4(1):950.
PMID: 34376784
Colorectal cancer liver metastasis (CRCLM) has two major histopathological growth patterns: angiogenic desmoplastic and non-angiogenic replacement. The replacement lesions obtain their blood supply through vessel co-option, wherein the cancer cells...
5.
Kuczynski E, Reynolds A
Angiogenesis
. 2019 Dec;
23(1):55-74.
PMID: 31865479
Vessel co-option is a non-angiogenic mechanism of tumour vascularisation in which cancer cells utilise pre-existing blood vessels instead of inducing new blood vessel formation. Vessel co-option has been observed across...
6.
Kuczynski E, Vermeulen P, Pezzella F, Kerbel R, Reynolds A
Nat Rev Clin Oncol
. 2019 Mar;
16(8):469-493.
PMID: 30816337
All solid tumours require a vascular supply in order to progress. Although the ability to induce angiogenesis (new blood vessel growth) has long been regarded as essential to this purpose,...
7.
Little R, Jamin Y, Boult J, Naish J, Watson Y, Cheung S, et al.
Radiology
. 2018 Jun;
288(3):739-747.
PMID: 29869970
Purpose To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility MRI measurements and to demonstrate the feasibility of translation of the technique for patients. Materials and...
8.
Donnem T, Reynolds A, Kuczynski E, Gatter K, Vermeulen P, Kerbel R, et al.
Nat Rev Cancer
. 2018 Mar;
18(5):323-336.
PMID: 29520090
Solid tumours need a blood supply, and a large body of evidence has previously suggested that they can grow only if they induce the development of new blood vessels, a...
9.
Van Dam P, van der Stok E, Teuwen L, Van den Eynden G, Illemann M, Frentzas S, et al.
Br J Cancer
. 2017 Oct;
117(10):1427-1441.
PMID: 28982110
Background: Liver metastases present with distinct histopathological growth patterns (HGPs), including the desmoplastic, pushing and replacement HGPs and two rarer HGPs. The HGPs are defined owing to the distinct interface...
10.
Robinson S, Boult J, Vasudev N, Reynolds A
Cancer Res
. 2017 Jun;
77(15):4127-4134.
PMID: 28566330
Antiangiogenic therapy is efficacious in metastatic renal cell carcinoma (mRCC). However, the ability of antiangiogenic drugs to delay tumor progression and extend survival is limited, due to either innate or...